PFE — Pfizer, Inc. Common Stock
Session close: $29.88. Regular-session share volume: 40,686,367. Change from previous close: -2.96%.
Key developments
Guggenheim raised its price target on Pfizer, reflecting an updated valuation outlook for the pharmaceutical company. The move followed a round of analyst revisions after Pfizer's third-quarter results, when Morgan Stanley cut its target while RBC and UBS raised theirs, with the latter two maintaining neutral or sector-perform stances.
Company news Guggenheim Adjusts Pfizer Price Target to $33 · Company news Analysts Adjust Price Targets for Pfizer Following Third-Quarter Results
On the business side, Pfizer announced a strategic collaboration with Flagship Pioneering's Pioneering Medicines unit aimed at discovering selective inhibitors for autoimmune diseases. Separately, CEO Albert Bourla outlined plans to enter the obesity market with berobenatide, acquired via the Metsera purchase, prioritizing differentiated dosing such as a potential monthly injection, though management does not expect a meaningful growth inflection until later years.
Company news Flagship Pioneering and Pfizer Announce Strategic Collaboration for Autoimmune Disease Research · Company news Pfizer CEO Outlines Strategy for Obesity Drug Market Entry
Pfizer Canada marked three decades as a partner of the Canadian Paralympic Committee, renaming its headquarters auditorium and unveiling a memorabilia wall.
Company news Pfizer Canada Celebrates 30-Year Partnership with Canadian Paralympic Committee
News sources
Company news Guggenheim Adjusts Pfizer Price Target to $33 · Company news Guggenheim Maintains Buy on Pfizer, Raises Price Target to $33 · Company news Pfizer Canada Celebrates 30-Year Partnership with Canadian Paralympic Committee · Company news Flagship Pioneering and Pfizer Announce Strategic Collaboration for Autoimmune Disease Research · Company news UBS Maintains Neutral on Pfizer, Raises Price Target to $30 · Company news Pfizer CEO Outlines Strategy for Obesity Drug Market Entry · Company news Scotiabank Maintains Sector Outperform on Pfizer, Raises Price Target to $35 · Company news Analysts Adjust Price Targets for Pfizer Following Third-Quarter Results · Company news Pfizer (PFE) Q3 Earnings Rebuild Confidence As New Drugs Gain Ground · Company news Missed Out On Pfizer's Run? Here Is What Holders Saw